Chitra Hosing

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas
    Chitra Hosing
    Stem Cell Transplantation and Cellular Therapy
    J Blood Med 1:49-55. 2010
  2. pmc CARs in chronic lymphocytic leukemia -- ready to drive
    Chitra Hosing
    Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Curr Hematol Malig Rep 8:60-70. 2013
  3. doi request reprint Hematopoietic stem cell mobilization with G-CSF
    Chitra Hosing
    Department of Stem Cell Transplantation and Cell Therapy, M D Anderson Cancer Center, Houston, TX, USA
    Methods Mol Biol 904:37-47. 2012
  4. ncbi request reprint Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
    C Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 36:157-62. 2005
  5. ncbi request reprint Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Haematol 133:533-7. 2006
  6. ncbi request reprint Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Am J Hematol 84:335-7. 2009
  7. ncbi request reprint High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age
    C Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 19:1166-71. 2008
  8. ncbi request reprint High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:1290-4. 2006
  9. ncbi request reprint Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Transfusion 51:1300-13. 2011
  10. pmc Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:674-81. 2011

Collaborators

Detail Information

Publications83

  1. pmc A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas
    Chitra Hosing
    Stem Cell Transplantation and Cellular Therapy
    J Blood Med 1:49-55. 2010
    ..Secondary objectives were to determine the expression of various dendritic cell subsets in the two groups and to determine the incidence of disease progression or relapse at 12 months...
  2. pmc CARs in chronic lymphocytic leukemia -- ready to drive
    Chitra Hosing
    Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Unit 423, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Curr Hematol Malig Rep 8:60-70. 2013
    ....
  3. doi request reprint Hematopoietic stem cell mobilization with G-CSF
    Chitra Hosing
    Department of Stem Cell Transplantation and Cell Therapy, M D Anderson Cancer Center, Houston, TX, USA
    Methods Mol Biol 904:37-47. 2012
    ..In most cases peripheral blood stem cells are collected after G-CSF administration. In this chapter we describe peripheral blood stem cell mobilization in autologous transplant patients and in allogeneic donors using G-CSF...
  4. ncbi request reprint Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
    C Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 36:157-62. 2005
    ..Thus, a second transplant may offer the possibility of long-term disease control in a subset of patients who have a 'low bulk' disease at the time of transplantation...
  5. ncbi request reprint Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Haematol 133:533-7. 2006
    ..A single fixed dose of pegfilgrastim was effective in mobilising adequate peripheral blood progenitor cells in patients with multiple myeloma. The efficacy and toxicity profile was similar to that described with filgrastim treatment...
  6. ncbi request reprint Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Am J Hematol 84:335-7. 2009
    ..In the subset of patients who undergo chemomobilization for non-Hodgkin's lymphoma platelet count at the time of mobilization is a predictor of mobilization failure...
  7. ncbi request reprint High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age
    C Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 19:1166-71. 2008
    ..We present a retrospective analysis of 99 consecutive patients with relapsed non-Hodgkin's lymphomas who were older than 65 years at the time of high-dose chemotherapy and autologous progenitor cell transplantation...
  8. ncbi request reprint High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:1290-4. 2006
    ..In conclusion, high-dose rituximab given during stem cell mobilization does not negatively affect stem cell mobilization kinetics...
  9. ncbi request reprint Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Transfusion 51:1300-13. 2011
    ....
  10. pmc Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:674-81. 2011
    ....
  11. doi request reprint Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
    Uday Popat
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:718-23. 2009
    ..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients...
  12. ncbi request reprint Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma...
  13. pmc Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS
    Borje S Andersson
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:893-900. 2011
    ..Additional studies to evaluate the antileukemic efficacy of Clo ± Flu with i.v. Bu as pretransplant conditioning therapy are warranted...
  14. doi request reprint Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome
    Madeleine Duvic
    Department of Dermatology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Oncol 28:2365-72. 2010
    ..We studied the safety and efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL)...
  15. ncbi request reprint Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 110:3456-62. 2007
    ..TRM rates are acceptable in this high-risk population but increase over time...
  16. pmc Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:410-7. 2013
    ..9, P = .008, HR for OS = 1.8, P = .07). Gem-Bu-Mel improved outcomes in this cohort analysis of patients with refractory/poor-risk relapsed HL and merits evaluation in randomized phase III trials...
  17. doi request reprint Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen...
  18. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
    ..Further studies should be conducted in carefully designed clinical trials in this patient population...
  19. ncbi request reprint Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
    Issa F Khouri
    Department of Blood and Marrow Transplantation, Unit 423, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:2240-7. 2005
    ....
  20. ncbi request reprint Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA
    Blood 107:3074-80. 2006
    ..Objective responses were observed in a substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression...
  21. pmc Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study
    Simrit Parmar
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    J Clin Oncol 29:294-302. 2011
    ....
  22. ncbi request reprint Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:1478-84. 2010
    ..In conclusion, a significant number of CD34+ cells can be safely collected in patients with CML who are on imatinib therapy, but CD34+ cell yields improve when imatinib is temporarily withheld...
  23. pmc Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan
    Betul Oran
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 13:454-62. 2007
    ..Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort...
  24. pmc Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:412-20. 2011
    ..Intravenous Bu-Mel was well tolerated. Disease control wa encouraging, and should be explored in larger phase II studies...
  25. pmc High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
    ..In conclusion, gemcitabine/busulfan/melphalan is a feasible regimen with substantial activity against a range of lymphoid malignancies. This regimen merits further evaluation in phase II and III trials...
  26. ncbi request reprint Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment
    Betul Oran
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 13:469-77. 2007
    ..Control of TAM generally requires response of associated infections and GVHD. TMA response may occur despite continuation of tacrolimus treatment...
  27. ncbi request reprint Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation
    Amin M Alousi
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 142:786-92. 2008
    ..We conclude that evidence of disease on PET/G scanning prior to transplantation is associated with an increased risk for relapse after ASCT. Transplantation regimens containing rituximab can reduce this risk, regardless of PET/G status...
  28. ncbi request reprint Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial
    Muzaffar H Qazilbash
    Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1401-7. 2008
    ..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM...
  29. ncbi request reprint Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1084-9. 2006
    ..The outcomes of salvage autologous or allogeneic transplants were analyzed retrospectively in patients relapsing after an autograft...
  30. doi request reprint Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections
    Dimpy P Shah
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Antimicrob Chemother 68:1872-80. 2013
    ....
  31. doi request reprint High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma
    Meghan Karuturi
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 19:991-4. 2013
    ..Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL...
  32. pmc Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:1841-5. 2011
    ....
  33. doi request reprint Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:1490-6. 2011
    ..Our results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS...
  34. ncbi request reprint Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
    Daniel Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 12:37-40. 2006
    ..All of these results indicate activity of extracorporeal photopheresis in acute and chronic GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies...
  35. ncbi request reprint Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Biol Blood Marrow Transplant 10:178-85. 2004
    ..It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients...
  36. ncbi request reprint Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    Yee Chung Cheng
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Hematol 90:627-34. 2009
    ..Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates...
  37. doi request reprint Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation
    Li Mei Poon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Biol Blood Marrow Transplant 19:1059-64. 2013
    ..8). Our data provide more insight into the disease behavior and treatment outcomes of ALL at relapse after HSCT against which future trials may be compared...
  38. pmc Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization
    Veronica R Smith
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 88:754-7. 2013
    ..93 × 10(6) /kg of body weight. The median CD34+ cell dose collected for patients with multiple myeloma was 8.81 × 10(6) /kg of body weight. Plerixafor was well tolerated; no grade 2 or higher non-hematologic toxic effects were observed...
  39. doi request reprint Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 119:6373-8. 2012
    ..The addition of (90)Y to the conditioning regimen appears to be effective in patients with chemorefractory disease. This trial was registered at www.clinicaltrials.gov as NCT00048737...
  40. ncbi request reprint Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 53:118-22. 2012
    ..These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion for auto HCT...
  41. ncbi request reprint Tumor necrosis factor-alpha blockade for the treatment of acute GVHD
    Daniel Couriel
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:649-54. 2004
    ..Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further...
  42. ncbi request reprint Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
    Issa F Khouri
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Tex 77030, USA
    Exp Hematol 32:28-35. 2004
    ..To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia...
  43. ncbi request reprint Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 4009, USA
    Leuk Lymphoma 44:829-32. 2003
    ..Lymphoma relapse occurred 4 months post-transplant. Immunosuppression withdrawal plus rituximab induced a complete response. He remains in complete remission (CR) 11 months post-immunosuppression withdrawal and 15 months post-transplant...
  44. ncbi request reprint Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma
    Gaurav C Parikh
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 15:812-6. 2009
    ..In this analysis, a melphalan (Mel) dose of 200 mg/m(2) was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM)...
  45. ncbi request reprint Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation
    Maricer P Escalon
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2419-23. 2004
    ..We investigated the safety and efficacy of nonmyeloablative stem-cell transplantation in these patients...
  46. ncbi request reprint Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
    Raymond Wong
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:3052-9. 2003
    ..Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease...
  47. ncbi request reprint Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, 77030, USA
    Am J Hematol 80:43-5. 2005
    ..The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity...
  48. ncbi request reprint Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction
    Muzaffar H Qazilbash
    Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:1265-70. 2009
    ..03). In conclusion, selected patients with a LVEF of < or =45% can safely receive allo-HCT without a significant increase in cardiac toxicity or NRM...
  49. doi request reprint Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation
    Jonas A de Souza
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 15:1094-9. 2009
    ..05). There were no differences in OS and NRM at day 100 and 1-year posttransplantation in the 3 groups by any GFR estimation method. In conclusion, a mild to moderate decrease in GFR was not associated with an increase in NRM...
  50. ncbi request reprint Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 11:108-14. 2005
    ....
  51. ncbi request reprint Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  52. ncbi request reprint Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era
    Richard Champlin
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S261-5. 2009
    ..This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions...
  53. ncbi request reprint Hyperacute GVHD: risk factors, outcomes, and clinical implications
    Rima M Saliba
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 109:2751-8. 2007
    ..In conclusion, hyperacute GVHD accounts for a substantial proportion of grade II-IV acute GVHD after HSCT. Patients at high risk or with a diagnosis of hyperacute GVHD should be included in clinical studies...
  54. ncbi request reprint Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
    L Lekakis
    Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Bone Marrow Transplant 38:421-6. 2006
    ..Two patients are alive and disease free; 4-year actuarial survival is 33 versus 0% for patients transplanted in remission versus in relapse. We concluded that disease status was the main determinant of treatment failure in this study...
  55. ncbi request reprint Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Transfusion 54:1081-7. 2014
    ..The aim of this study was to assess the predictive value of this formula...
  56. doi request reprint Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease
    Simrit Parmar
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:2884-7. 2009
    ..05). We conclude that MICA may represent novel a transplantation antigen recognized by human allogeneic T cells. This study was registered at ClinicalTrials.gov (Identifier NCT00506922)...
  57. ncbi request reprint Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma
    Elias Jabbour
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2481-9. 2007
    ....
  58. pmc Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation
    Fleur M Aung
    Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 160:798-805. 2013
    ..Hence, after major ABO-mismatched HSCT, the incidence of PRCA was 7·5% and it resolved spontaneously or after withdrawal of immunosuppression in the majority of patients...
  59. pmc Cord-blood engraftment with ex vivo mesenchymal-cell coculture
    Marcos de Lima
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 367:2305-15. 2012
    ..We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells...
  60. pmc An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection
    Roy F Chemaly
    Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Infect Dis 206:1367-71. 2012
    ..Because the intermittent schedule is easy to administer and has a higher efficacy than the continuous schedule, we recommend the intermittent schedule for patients who are at risk for RSV LRTI. Clinical Trials Registration. NCT00500578...
  61. ncbi request reprint Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant
    Muzaffar H Qazilbash
    Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1066-72. 2007
    ..02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma...
  62. pmc Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma
    Yvonne A Efebera
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:1122-9. 2010
    ..The use of RIC allo-HSCT earlier in the course of the disease may offer the greatest benefit...
  63. ncbi request reprint Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, USA
    Biol Blood Marrow Transplant 18:1835-44. 2012
    ..These results indicate that a TCR graft followed by effective control of GVHD posttransplantation may lower NRM and improve survival after haploidentical SCT...
  64. ncbi request reprint Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 122:128-34. 2003
    ..One patient was changed to cyclosporine. In most patients, subsequent treatment with tacrolimus was well tolerated without recurrence of neurotoxicity...
  65. ncbi request reprint Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
    C Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 13:450-9. 2002
    ....
  66. ncbi request reprint West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review
    David S Hong
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Infect Dis 37:1044-9. 2003
    ..We describe here 2 patients who underwent hematopoietic transplantation at our institution and subsequently developed fatal West Nile virus infections...
  67. ncbi request reprint Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus
    Ola Khorshid
    Division of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Rheumatol 31:2513-6. 2004
    ..We describe a patient with both diffuse cutaneous SSc and systemic lupus erythematosus who showed mixed chimerism 29 months after undergoing nonmyeloablative stem cell transplant. She experienced remission of both diseases...
  68. ncbi request reprint Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications
    Richard Champlin
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:94-100; discussion 103-7. 2003
    ....
  69. ncbi request reprint Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
    U Popat
    Department of Blood and Marrow Transplant, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Bone Marrow Transplant 33:1015-23. 2004
    ..We conclude that autologous transplantation is an effective salvage treatment for recurrent HL...
  70. ncbi request reprint The choice of allogeneic or autologous hematopoietic transplantation for NHL
    C Hosing
    Department of Blood and Marrow Transplantation, The Univeristy of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cytotherapy 4:259-69. 2002
    ..Nonablative allogeneic transplants are a promising strategy, particularly for patients with indolent lymphoid malignancies...
  71. ncbi request reprint Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
    M H Qazilbash
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 39:279-83. 2007
    ..Patients with relapsed disease at transplant, and an interval of >12 months between diagnosis and autotransplant, had a shorter OS (P=0.0004 and 0.04). HDT and autologous transplant is safe and feasible in elderly myeloma patients...
  72. pmc Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial
    M De Lima
    Department of Stem Cell Transplantation and Cell Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 41:771-8. 2008
    ..Median time to neutrophil and platelet engraftment was 30 (range, 16-46) and 48 (range, 35-105) days. There were no cases of grades 3-4 acute graft-versus-host disease (GVHD) and 100-day survival was 90%. This strategy is feasible...
  73. ncbi request reprint Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
    P Anderlini
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 35:943-51. 2005
    ..03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival...
  74. ncbi request reprint Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
    E Ozdemir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Bone Marrow Transplant 40:125-36. 2007
    ..The remaining patients had an intermediate incidence of 32%...
  75. ncbi request reprint Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
    M De Lima
    Department of Stem Cell Transplantation and Cell Therapy, U T M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 22:258-64. 2008
    ..Median follow-up was 37 months. Median event-free and overall survival was 6 and 11 months. GO 2 mg m(-2) can be safely added to fludarabine/melphalan, and this regimen merits further evaluation...
  76. ncbi request reprint Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma
    C Hosing
    Departments of Blood and Marrow Transplantation and Lymphoma, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 14:737-44. 2003
    ..The aim of this study was to compare the outcomes of high-dose therapy (HDT) and allogeneic versus autologous hematopoietic stem cell transplantation (SCT) in patients with refractory or recurrent indolent non-Hodgkin's lymphoma (NHL)...
  77. doi request reprint The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation
    Roy F Chemaly
    Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 119:2738-45; quiz 2969. 2012
    ..Patients with leukemia and HSCT are at risk for serious PIV infections, including PIV pneumonia, with a significant mortality rate. We identified multiple risk factors for progression to pneumonia and death...
  78. doi request reprint Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab
    Christelle Kassis
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 16:1265-71. 2010
    ..Immunoprophylaxis with palivizumab, administered to high-risk patients, complemented strict infection control intervention. Thus, the role of palivizumab in the control of RSV hospital outbreaks merits further investigation...
  79. ncbi request reprint Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation
    D R Couriel
    Department of Blood and Marrow Transplantation, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 30:543-6. 2002
    ..The duration of immunosuppressive treatment has varied in different reports, and there is a risk of recurrence when immunosuppression is tapered...
  80. ncbi request reprint Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results
    N Apisarnthanarax
    Department of Dermatology, MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 31:459-65. 2003
    ..However, most patients continue to require at least some chronic therapy and cGVHD-related morbidity and mortality remain high...
  81. ncbi request reprint Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease
    D R Couriel
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 130:409-17. 2005
    ..Controlled trials comparing this approach with alternative strategies to determine which can best achieve the goal of GVHD-free survival are warranted...
  82. pmc Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment
    G S Falchook
    Department of Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 20:1080-5. 2009
    ....